|
1
|
Johannessen TC, Prestegarden L, Grudic A,
Hegi ME, Tysnes BB and Bjerkvig R: The DNA repair protein ALKBH2
mediates temozolomide resistance in human glioblastoma cells. Neuro
Oncol. 15:269–278. 2013. View Article : Google Scholar :
|
|
2
|
Hill VK, Shinawi T, Ricketts CJ, Krex D,
Schackert G, Bauer J, Wei W, Cruickshank G, Maher ER and Latif F:
Stability of the CpG island methylator phenotype during glioma
progression and identification of methylated loci in secondary
glioblastomas. BMC Cancer. 14:5062014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Agarwal S, Sharma MC and Jha P, Pathak P,
Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK and Jha
P: Comparative study of IDH1 mutations in gliomas by
immunohistochemistry and DNA sequencing. Neuro Oncol. 15:718–726.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Henriksen M, Johnsen KB, Andersen HH,
Pilgaard L and Duroux M: MicroRNA expression signatures determine
prognosis and survival in glioblastoma multiforme - a systematic
overview. Mol Neurobiol. 50:896–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blenkiron C and Miska EA: MiRNAs in
cancer: Approaches, aetiology, diagnostics and therapy. Hum Mol
Genet. 16(Spec No 1): R106–R113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang W, Zhang J, Yan W, You G, Bao Z, Li
S, Kang C, Jiang C, You Y, Zhang Y, et al: Whole-genome microRNA
expression profiling identifies a 5-microRNA signature as a
prognostic biomarker in Chinese patients with primary glioblastoma
multiforme. Cancer. 119:814–824. 2013. View Article : Google Scholar
|
|
8
|
Srinivasan S, Patric IR and Somasundaram
K: A ten-microRNA expression signature predicts survival in
glioblastoma. PLoS One. 6:e174382011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Novakova J, Slaby O, Vyzula R and Michalek
J: MicroRNA involvement in glioblastoma pathogenesis. Biochem
Biophys Res Commun. 386:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sempere LF, Freemantle S, Pitha-Rowe I,
Moss E, Dmitrovsky E and Ambros V: Expression profiling of
mammalian microRNAs uncovers a subset of brain-expressed microRNAs
with possible roles in murine and human neuronal differentiation.
Genome Biol. 5:R132004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z, Bao Z, Yan W, You G, Wang Y, Li X
and Zhang W: Isocitrate dehydrogenase 1 (IDH1) mutation-specific
microRNA signature predicts favorable prognosis in glioblastoma
patients with IDH1 wild type. J Exp Clin Cancer Res. 32:592013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma X, Yoshimoto K, Guan Y, Hata N,
Mizoguchi M, Sagata N, Murata H, Kuga D, Amano T, Nakamizo A and
Sasaki T: Associations between microRNA expression and mesenchymal
marker gene expression in glioblastoma. Neuro Oncol. 14:1153–1162.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Papagiannakopoulos T, Friedmann-Morvinski
D, Neveu P, Dugas JC, Gill RM, Huillard E, Liu C, Zong H, Rowitch
DH and Barres BA: Pro-neural miR-128 is a glioma tumor suppressor
that targets mitogenic kinases. Oncogene. 31:1884–1895. 2012.
View Article : Google Scholar
|
|
14
|
Cui JG, Zhao Y, Sethi P, Li YY, Mahta A,
Culicchia F and Lukiw WJ: Micro-RNA-128 (miRNA-128) down-regulation
in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key
regulators of brain cell proliferation. J Neurooncol. 98:297–304.
2010. View Article : Google Scholar
|
|
15
|
Sanson M, Marie Y, Paris S, Idbaih A,
Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K,
Hoang-Xuan K and Delattre JY: Isocitrate dehydrogenase 1 codon 132
mutation is an important prognostic biomarker in gliomas. J Clin
Oncol. 27:4150–4154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang
P, Yu W, Li Z, Gong L, Peng Y, et al: Glioma-derived mutations in
IDH1 dominantly inhibit IDH1 catalytic activity and induce
HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu YL, DeLay M, Jahangiri A, Molinaro AM,
Rose SD, Carbonell WS and Aghi MK: Hypoxia-induced autophagy
promotes tumor cell survival and adaptation to antiangiogenic
treatment in glioblastoma. Cancer Res. 72:1773–1783. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lakomy R, Sana J, Hankeova S, Fadrus P,
Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R,
et al: MiR-195, miR-196b, miR-181c, miR-21 expression levels and
O-6-methylguanine-DNA methyltransferase methylation status are
associated with clinical outcome in glioblastoma patients. Cancer
Sci. 102:2186–2190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Godlewski J, Nowicki MO, Bronisz A,
Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca
EA and Lawler S: Targeting of the Bmi-1 oncogene/stem cell renewal
factor by microRNA-128 inhibits glioma proliferation and
self-renewal. Cancer Res. 68:9125–9130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bralten LB, Kloosterhof NK, Balvers R,
Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM,
Jansen EE, et al: IDH1 R132H decreases proliferation of glioma cell
lines in vitro and in vivo. Ann Neurol. 69:455–463. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu J, Zuo J, Xu Q, Wang X, Wang Z and
Zhou D: Isocitrate dehydrogenase mutations may be a protective
mechanism in glioma patients. Med Hypotheses. 76:602–603. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ciafrè SA, Galardi S, Mangiola A, Ferracin
M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG:
Extensive modulation of a set of microRNAs in primary
glio-blastoma. Biochem Biophys Res Commun. 334:1351–1358. 2005.
View Article : Google Scholar
|
|
23
|
Peruzzi P, Bronisz A, Nowicki MO, Wang Y,
Ogawa D, Price R, Nakano I, Kwon CH, Hayes J, Lawler SE, et al:
MicroRNA-128 coordinately targets polycomb repressor complexes in
glioma stem cells. Neuro Oncol. 15:1212–1224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi ZM, Wang J, Yan Z, You YP, Li CY, Qian
X, Yin Y, Zhao P, Wang YY, Wang XF, et al: MiR-128 inhibits tumor
growth and angiogenesis by targeting p70S6K1. PLoS One.
7:e327092012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Venkataraman S, Alimova I, Fan R, Harris
P, Foreman N and Vibhakar R: MicroRNA 128a increases intracellular
ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer
cell growth by promoting senescence. PLoS One. 5:e107482010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kamiyama H, Takano S, Tsuboi K and
Matsumura A: Anti-angiogenic effects of SN38 (active metabolite of
irinotecan): Inhibition of hypoxia-inducible factor 1 alpha
(HIF-1alpha)/vascular endothelial growth factor (VEGF) expression
of glioma and growth of endothelial cells. J Cancer Res Clin Oncol.
131:205–213. 2005. View Article : Google Scholar
|
|
27
|
Ichimura K: Molecular pathogenesis of IDH
mutations in gliomas. Brain Tumor Pathol. 29:131–139. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nanta R, Kumar D, Meeker D, et al:
NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal
transition and human prostate cancer stem cell growth in NOD/SCID
IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis.
2:e422013. View Article : Google Scholar
|
|
29
|
Li J, Gong LY, Song LB, Jiang LL, Liu LP,
Wu J, Yuan J, Cai JC, He M, Wang L, et al: Oncoprotein Bmi-1
renders apoptotic resistance to glioma cells through activation of
the IKK-nuclear factor-kappaB Pathway. Am J Pathol. 176:699–709.
2010. View Article : Google Scholar :
|
|
30
|
Farivar S, Zati Keikha R, Shiari R and
Jadali F: Expression of bmi-1 in pediatric brain tumors as a new
independent prognostic marker of patient survival. Biomed Res Int.
2013:1925482013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siddique HR, Parray A, Zhong W, Karnes RJ,
Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR and Saleem M:
BMI1, stem cell factor acting as novel serum-biomarker for
Caucasian and African-American prostate cancer. PLoS One.
8:e529932013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bruggeman SW, Hulsman D, Tanger E, Buckle
T, Blom M, Zevenhoven J, van Tellingen O and van Lohuizen M: Bmi1
controls tumor development in an Ink4a/Arf-independent manner in a
mouse model for glioma. Cancer Cell. 12:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
